Human monoclonal antibodies for the treatment and prevention of COVID-2019 infections are being developed by National Resilience (previously Ology Bioservices) in collaboration with Vanderbilt University Medical Center (VUMC) under the Pandemic Prevention Platform (P3) network of the U.S. Defense Advanced Research Projects Agency (DARPA). Preclinical development is underway in the US.

In April 2021, Ology Bioservices was acquired and merged into National Resilience ^[1] .

As at August 2024, no recent reports of development had been identified for preclinical development in COVID-2019-infections in USA (Parenteral), preclinical development in COVID-2019-infections (Prevention) in USA (Parenteral).

In March 2020, Twist Bioscience Corporation entered into a collaboration agreement with Vanderbilt University Medical Center (VUMC) to supply synthetic genes and antibodies for the development of therapies for COVID-19. Twist Biopharma will provide custom antibody drug discovery libraries and will screen the libraries for potential antibody therapeutics that would treat patients with COVID-19. ^[2]

Prior to March 2020, Ology Bioservices (now National Resilience) and Vanderbilt University Medical Center (VUMC) entered into an agreement to develop and manufacture a monoclonal antibody for treatment and prevention of infection with the COVID-19 virus. The aim of the program is to rapidly and efficiently deliver the antibody to the Department of Defense. Under the proposed terms of the pending agreement with VUMC, researchers in the Vanderbilt Vaccine Center (VVC) will be tasked in this program with rapid antibody discovery efforts as a performance site for the Pandemic Prevention Platform (P3) network of the U.S. Defense Advanced Research Projects Agency (DARPA). ^[3]

Prior to July 2020, the neutralizing monoclonal antibodies were tested in small animals and non-human primates. The monoclonal antibodies demonstrated positive results in preclinical studies ^[4] .

Financing information

In March 2020, the Department of Defense (DOD) awarded a contract valued at $US14 million with Ology Bioservices to develop and manufacture a monoclonal antibody for treatment and prevention of infection with the COVID-19 virus. The work is supported by the Office of the Assistant Secretary of Defense for Health Affairs with funding from the Defense Health Agency. Under this program, Ology Bioservices will work with Vanderbilt University Medical Center (VUMC) to develop and manufacture the monoclonal antibody. The aim of the program is to rapidly and efficiently deliver the antibody to the Department of Defense ^[3] .